X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases

Brain Metastases Clinical Trial

Official title:

Efficacy and Safety of X-396(Ensartinib) in ALK-Positive NSCLC Patients With Brain Metastases: A Phase Ⅱ, Open-Label, Single Arm, Multicenter Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03753685
• Other study ID #: BTP-42324-IIT
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: December 2018
• Est. completion date: October 2020

Study information

• Verified date: November 2018
• Source: Fudan University
• Contact: Jue Feng
• Phone: 021-64175590-88900
• Email: 13788956275[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To assess efficacy and safety of oral X-396 (Ensartinib) capsule in Chinese ALK-positive NSCLC patients with brain metastases, eligible patients will be enrolled with objective responses being primary outcome measures.

Description:

In this phase Ⅱ, open-label, single arm, multicenter study, efficacy and safety of oral X-396 capsule (Ensartinib) in 37 Chinese ALK-positive NSCLC patients with brain metastases will be assessed. Eligible patients will receive 225mg X-396 capsules once daily and objective responses of brain metastasis based on investigator assessment according to Response Assessment in Neuro-Oncology (RANO) are primary outcome measures.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 37
• Est. completion date: October 2020
• Est. primary completion date: July 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 1. Histologically or cytologically confirmed locally advance or recurrent/metastatic NSCLC that was positive for ALK mutations.

2. Contrast-enhanced MRI or CT confirmed parenchymal brain metastases with at least one measurable lesion (according to RANO and RECIST 1.1), which was not previously treated with radiotherapy.

3. At most once treated with chemotherapy, which must have been completed at least 4 weeks before the initiation of study treatment. Any adverse events related to previous chemotherapy treatment have disappeared.

4. Female or male, 18 years of age or older 5. A Karnofsky Performance Status score of at least 60. 6. An expected survival time of at least 12 weeks. 7. Adequate organ functions, defined as absolute neutrophils count =1.5*10^9/L,platelets count =80*10^9/L, hemoglobin concentration= 9 g/dL, total bilirubin =1.5 *ULN (upper limits of normal), ALT=2.5 *ULN, AST=2.5 *ULN, creatinine=1.5 *ULN.

8. Drug related toxicities has been relieved to grade 1 (based on NCI CTCAE v4.03), except for hair loss.

9. Being willing and able to comply with scheduled visits, treatment plans, laboratory tests and other study procedures.

10. Signed and dated informed consent.

Exclusion Criteria:

• 1. Currently under treatment of other systemic anti-cancer therapies. 2. Evidence of active malignancy within last 5 years. 3. Patients who participated in other clinical trials within last 4 weeks before the initiation of study treatment.

4. Patients who received surgery or immunotherapy within last 4 weeks before the initiation of study treatment, or received radiotherapy within last 2 weeks before the initiation of study treatment.

5. Patients who previously received organ transplantation or stem cell transplantation.

6. Patients with clinically significant cardiovascular and cerebrovascular diseases.

7. Patients with dysphagia, active gastrointestinal diseases or other conditions that will interfere significantly with the absorption, distribution, metabolism or excretion of study medication.

8. Patients who are active carrier of hepatitis B (HBsAg positive and HBV-DNA =500IU/mL), hepatitis C virus antibody, treponema pallidum antibody or HIV antibody.

9. Patients with interstitial lung disease history or signs of active interstitial lung disease.

10. Pregnant and lactating women. 11. Patients with known allergy or delayed hypersensitivity reaction to study drug or its excipients.

12. Patients who need to receive drugs which could induce QT/QTc interval prolongation or torsade de pointes, or drugs which are potent CYP3A4 inhibitors or inducers within last 14 days before the initiation of study treatment and during the study.

13. Patients who are currently under treatment of warfarin or other coumarin anticoagulants.

14. Patients with other illness or medical conditions potentially interfering with the study treatment.

Related Conditions & MeSH terms

• Brain Metastases
• Brain Neoplasms
• Carcinoma, Non-Small-Cell Lung
• Neoplasm Metastasis
• Neoplasms, Second Primary
• Nonsmall Cell Lung Cancer

Intervention

Drug:
• X-396(Ensartinib) Capsule
All consented, enrolled, eligible patients receive X-396 capsules, 225mg once daily.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Fudan University	Betta Pharmaceuticals Co.,Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Intracranial objective response rate (iORR) based on investigator assessment according to RNAO-BM.	iORR per RANO-BM calculated as the proportion of patients with a best intracranial overall response defined as complete response (CR) or partial response (PR), based on investigator assessment.	12 weeks
Secondary	Disease control rate based on intracranial response (iDCR) according to RANO-BM.	Defined as the percentage of patients who have achieved intracranial overall response of CR, PR and stable disease (SD), assessed by investigator.	12 weeks
Secondary	Progression-free survival based on intracranial response (iPFS) according to RANO-BM	Defined as time from first dose of X-396 capsule to intracranial disease progression or death due to any causes, assessed by investigator.	36 months
Secondary	Time to progression based on intracranial response (iTTP) according to RANO-BM.	Defined as time from first dose of X-396 capsule to intracranial disease progression, assessed by investigator.	36 months
Secondary	Duration of response based on intracranial response (iDOR) according to RANO-BM.	Defined as time from documentation of intracranial response (CR or PR) to intracranial disease progression or death, assessed by investigator.	36 months
Secondary	Intracranial objective response rate (iORR) based on intracranial response according to RECIST 1.1	iORR per RECIST 1.1 calculated as the proportion of patients with a best intracranial overall response defined as complete response (CR) or partial response (PR), based on investigator assessment.	12 weeks
Secondary	Disease control rate based on intracranial response (iDCR) according to RECIST 1.1	Defined as the percentage of patients who have achieved intracranial overall response of CR, PR and stable disease (SD), assessed by investigator.	12 weeks
Secondary	Progression-free survival based on intracranial response (iPFS) according to RECIST 1.1	Defined as time from first dose of X-396 capsule to intracranial disease progression or death due to any causes, assessed by investigator.	36 months
Secondary	Time to progression based on intracranial response (iTTP) according to RECIST 1.1	Defined as time from first dose of X-396 capsule to intracranial disease progression, assessed by investigator.	36 months
Secondary	Duration of response based on intracranial response (iDOR) according to RECIST 1.1	Defined as time from documentation of intracranial response (CR or PR) to intracranial disease progression or death, assessed by investigator.	36 months
Secondary	Objective response rate (ORR) based on overall response according to RECIST 1.1.	ORR per RECIST 1.1 calculated as the proportion of patients with a best overall response defined as complete response (CR) or partial response (PR), based on investigator assessment.	12 weeks
Secondary	Disease control rate based on overall response (DCR) according to RECIST 1.1	Defined as the percentage of patients who have achieved overall response of CR, PR and stable disease (SD), assessed by investigator.	12 weeks
Secondary	Progression-free survival based on overall response (PFS) according to RECIST 1.1	Defined as time from first dose of X-396 capsule to overall disease progression or death due to any causes, assessed by investigator.	36 months
Secondary	Time to progression based on overall response (TTP) according to RECIST 1.1	Defined as time from first dose of X-396 capsule to overall disease progression, assessed by investigator.	36 months
Secondary	Duration of response based on overall response (DOR) according to RECIST 1.1	Defined as time from documentation of overall response (CR or PR) to overall disease progression or death, assessed by investigator.	36 months
Secondary	Overall survival (OS)	Defined as time from first dose of X-396 to death due to any causes.	36 months
Secondary	Incidence of patients experiencing adverse events.	Incidence of adverse events occurred during the study (from the timeoint of signing a informed consent form to 30days after the end of trial).	36 months